Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start
Data Mixed In Spinocerebellar Ataxia Study, But Zavegepant PDUFA Date Set
The road to clinical success outside of its CGRP pipeline always has been rocky for Biohaven • Source: Shutterstock